Long Run Wealth Advisors LLC Has $3.55 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Long Run Wealth Advisors LLC decreased its stake in Boston Scientific Co. (NYSE:BSX) by 8.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 39,719 shares of the medical equipment provider’s stock after selling 3,624 shares during the period. Long Run Wealth Advisors LLC’s holdings in Boston Scientific were worth $3,548,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of BSX. Vestia Personal Wealth Advisors lifted its position in shares of Boston Scientific by 17.2% in the 4th quarter. Vestia Personal Wealth Advisors now owns 3,022 shares of the medical equipment provider’s stock worth $270,000 after acquiring an additional 443 shares during the period. Choreo LLC lifted its position in Boston Scientific by 61.1% in the fourth quarter. Choreo LLC now owns 50,592 shares of the medical equipment provider’s stock worth $4,536,000 after purchasing an additional 19,187 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Boston Scientific by 8.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,313 shares of the medical equipment provider’s stock worth $16,372,000 after buying an additional 14,586 shares in the last quarter. Jackson Wealth Management LLC increased its holdings in Boston Scientific by 1,201.1% in the 4th quarter. Jackson Wealth Management LLC now owns 51,770 shares of the medical equipment provider’s stock valued at $4,624,000 after buying an additional 47,791 shares during the period. Finally, Stratos Wealth Advisors LLC raised its stake in shares of Boston Scientific by 2.3% in the 4th quarter. Stratos Wealth Advisors LLC now owns 6,569 shares of the medical equipment provider’s stock valued at $587,000 after buying an additional 150 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BSX shares. Citigroup lifted their target price on shares of Boston Scientific from $98.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, January 29th. Wells Fargo & Company upped their price target on Boston Scientific from $98.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. BTIG Research raised their price target on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 27th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $100.39.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $104.95 on Thursday. The firm has a market cap of $154.68 billion, a price-to-earnings ratio of 86.73, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80. The stock’s 50-day moving average is $94.01 and its 200-day moving average is $86.71. Boston Scientific Co. has a one year low of $64.08 and a one year high of $107.17. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. Equities analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company’s stock, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,302 shares of company stock worth $4,464,725 over the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.